---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-26-001349"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2026-08-06T12:15:17+00:00"
generated_at: "2026-08-06T12:20:13.555105+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical completes dosing of all 20 participants in Phase 1 trial of NPM-139 semaglutide implant

## Summary
- First 10 participants dosed July 29, 2026; remaining 10 dosed one week later; all insertions successful.
- Top-line data from the 20-participant SLIM-1 trial expected in November 2026.
- Trial includes low-dose NPM-139 and Wegovy comparator to assess safety, tolerability, PK, and weight change.
- Preclinical studies demonstrated sustainable 20% weight reduction in animal models.
- July 2026 agreement with Novo Nordisk to evaluate NPM-139 and NanoPortal implant technology.

## SEC filing metadata
- accession: 0001753926-26-001349
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2026-08-06T12:15:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/0001753926-26-001349-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/vani-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-26-001349
- JSON: https://secwatch.observer/filing/0001753926-26-001349.json
- Plain text: https://secwatch.observer/filing/0001753926-26-001349.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.